ArticlePersonalized medicine2009
Next-generation sequencing of cancer genomes: back to the future.
Article in Personalized medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 29 citations in OpenAlex.
- Duplex sequencing identifies genomic features that determine susceptibility to benzo(a)pyrene-induced in vivo mutations.BMC genomics · 2022Article
- Molecular Subtyping of Pancreatic Cancer: Translating Genomics and Transcriptomics into the Clinic.Journal of Cancer · 2017Review
- Review
- Microbes, metagenomes and marine mammals: enabling the next generation of scientist to enter the genomic era.BMC genomics · 2013Article
- Mutational analysis of breast cancer: guiding personalized treatments.Breast (Edinburgh, Scotland) · 2013Review
- Are results of targeted gene sequencing ready to be used for clinical decision making for patients with acute myelogenous leukemia?Current hematologic malignancy reports · 2013Review
- The Future of Children's Health in the Genomic Era.Rambam Maimonides medical journal · 2011Article
- An integrated genomic approach to the assessment and treatment of acute myeloid leukemia.Seminars in oncology · 2011Review
- Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression.The Journal of clinical investigation · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The systematic karyotyping of bone marrow cells was the first genomic approach used to personalize therapy for patients with leukemia. The paradigm established by cytogenetic studies in leukemia (from gene discovery to therapeutic intervention) now has the potential to be rapidly extended with the use of whole-genome sequencing approaches for cancer, which are now possible. We are now entering a period of exponential growth in cancer gene discovery that will provide many novel therapeutic targets for a large number of cancer types. Establishing the pathogenetic relevance of individual mutations is a major challenge that must be solved. However, after thousands of cancer genomes have been sequenced, the genetic rules of cancer will become known and new approaches for diagnosis, risk stratification and individualized treatment of cancer patients will surely follow.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.